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Purpose: To investigate the patterns of care for patients with nasopharyngeal carcinoma (NPC) in South Korea.
Materials and Methods: A multi-institutional retrospective study was performed (Korean Radiation Oncology Group [KROG] 
11-06) on a total of 1,445 patients from 15 institutions.
Results: Of the 1,445 patients, more than half were stages III (39.9%) and IV (35.8%). In addition to patterns of care, we also 
investigated trends over time with the periods 1988–1993, 1994–2002, and 2003–2011. The frequencies of magnetic resonance 
imaging and positron emission tomography-computed tomography were markedly increased in the third period compared to 
previous 2 periods. Concurrent chemoradiation (CCRT) was performed on 894 patients (61.9%), neoadjuvant chemotherapy on 468 
patients (32.4%), and adjuvant chemotherapy on 366 patients (25.3%). Of stage II–IV patients, CCRT performed on 78.8% in 2003–
2011 compared to 15.0% in 1988–1993. For patients treated with CCRT, cisplatin was the most commonly used agent in 81.3% of 
patients. Over the periods of time, commonly used radiotherapy (RT) techniques were changed from 2-dimensional RT (1988–1993, 
92.5%) to 3-dimensional RT (2003–2011, 35.5%) or intensity-modulated RT (IMRT; 2003–2011, 56.5%). Median RT doses given to 
primary tumors, high-risk lymphatics, and low-risk lymphatics were 70.0 Gy, 58.1 Gy, and 48.0 Gy, respectively. Adoption of IMRT 
increased the dose per fraction and escalated total radiation dose.
Conclusion: Assessment of the patterns of care for NPC patients in South Korea demonstrated that management for NPC including 
diagnostic imaging, treatment regimen, RT techniques and dose schedule, advanced in accordance with the international guidelines.
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Introduction
Nasopharyngeal carcinoma (NPC) shows markedly geographic 
and racial variations in incidence. In southern China, NPC is 
the most common head and neck cancer, but in the Western 
world, it is a rare disease with an incidence of less than 1 per 
100,000 [1]. South Korea is known to show an intermediate 
incidence, which is lower than that of the endemic area and 
higher than that of the Western world. Annual report of cancer 
statistics in South Korea presents that a total of 379 patients 
were diagnosed as NPC in 2012, accounting for 0.2% of all 
malignancies [2].
Because of difficulty in surgical resection with an adequate 
margin, radiotherapy (RT) is the gold standard treatment of NPC 
[3,4]. Current guidelines recommend RT alone for the treatment 
of patients of stage I and concurrent chemoradiotherapy (CCRT) 
for the treatment of those of higher stages [5]. However, 
adequate RT planning is challenging because critical organs 
including brainstem, temporal lobe and parotid glands are 
closely located to nasopharynx. It is still uncertain whether 
adjuvant or neoadjuvant chemotherapy provide an additional 
benefit over definitive CCRT. Variations in details of RT dose 
prescription or decision of adjuvant treatment might exist. 
Reviewing the current patterns of care in multiple institutions 
would be valuable to each clinician to decide treatment policy 
in daily clinic. Therefore, we conducted a multi-institutional 
study of NPC to assess current clinical practice.
Materials and Methods
To assess the patterns of care, a multi-institutional retrospective 
study of NPC (Korean Radiation Oncology Group [KROG] 11-
06) was performed through the head and neck committee of 
the Korean Society of Radiation Oncology. Data were collected 
from the medical records of 1,476 primary NPC patients treated 
at 15 institutions in South Korea between September 1988 and 
October 2011. Eligible criteria were as follows: 1) pathologically 
proven NPC; 2) stage I to IVb NPC according to the American 
Joint Committee on Cancer (AJCC) staging, the 6th edition; 3) 
age over 18 years; and 4) the Eastern Cooperative Oncology 
Group (ECOG) performance status ≤2. Patients who had 
undergone previous surgery or RT to the head and neck, and 
those with distant metastasis at initial diagnosis were excluded 
from the study.
In this study, to assess the patterns of care, we collected 
the data of patient and tumor characteristics, diagnostic 
modality, RT technique, RT dose schedule, chemotherapy 
schedule, treatment outcomes, and salvage treatment. Cases 
with missing data were included in analysis to investigate as 
many patients as possible. In total, 31 patients were excluded. 
Reasons for exclusion were as follows: 7 patients below 18 
years, 2 patients with ECOG 3, 16 patients given lower than 
45 Gy to primary mass, and 6 patients with lack of data of RT 
dose. Finally 1,445 patients were analyzed.
Prior to patient enrollment, Institutional Review Board 
approval was obtained at each participating center, and 
data of eligible patients were collected through web-based 
system developed by KROG and were transferred to the KROG 
Data Center (National Cancer Center, Goyang, Korea). RT, 
chemotherapy, toxicity, recurrence, and survival reports of all 
patients were reviewed according to a centralized quality-
assurance program.
Response was evaluated according to World Health 
Organization (WHO) criteria. Overall survival (OS) was defined as 
the time from pathologic diagnosis of NPC to death of all cause. 
Recurrences were analyzed to evaluate the failure pattern. 
Recurrences in the primary site and the cervical lymphatic area 
were defined as locoregional ones. Recurrences involving other 
sites were regarded as distant metastasis. Survival time was 
estimated by the Kaplan-Meier method. Survival differences 
over time were analyzed using the log-rank test. A p-value of 
<0.05 (two-sided test) was considered significant. 
Results
1. Patient characteristics
Patient characteristics are listed in Table 1. The median age of 
the 1,445 patients was 51 years and ranged between 18 and 86 
years. The number of male patients was 1,054 (72.9%). Based 
on WHO classification published in 1991, histopathological 
groups are divided into two major types: keratinizing 
squamous cell carcinoma in 225 patients (15.6%) and non-
keratinizing carcinoma in 1,176 patients (81.4%). Epstein-Barr 
virus (EBV) status was available only in 258 patients, of whom 
164 (11.3%) were positive for EBV. When EBV status was 
compared according to pathologic types, patients with non-
keratinizing carcinoma showed a higher incidence of EBV than 
those with keratinizing squamous cell carcinoma (68.8% vs. 
25.9%). AJCC stages were as follows: stage I, 71 patients (4.9%); 
stage II, 279 patients (19.3%); stage III, 577 patients (39.9%); 
and stage IV, 518 patients (35.8%). 
2. Diagnosis
The most common chief complaint was a palpable neck mass 
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(41.4%). Nasal symptoms (epistaxis, nasal stuffiness, and 
rhinorrhea) were observed in 25.8% of the patients. Aural 
symptoms (tinnitus, hearing impairment, and otorrhea) were 
observed in 16.5% of the patients, and cranial nerve palsy was 
observed in 8.9%. Other complaints were headache (4.7%), 
incidental finding (1.2%), throat symptom (1.2%), and pain 
(1.1%).
Neck computed tomography (CT, 94.1%), neck magnetic 
resonance imaging (MRI,  69.8%),  positron emission 
tomography-computed tomography (PET-CT, 46.6%), bone scan 
(35.8%), and abdominal ultrasonography (US) or CT (29.4%) 
were used for diagnostic imaging. Commonly used imaging 
studies were changed over the periods studied. Neck CT was 
performed on almost all patients in the 3 periods (1988–1993, 
97.5%; 1994–2002, 92.1%; and 2003–2011, 95.1%). The 
frequency of MRI was markedly increased in the third period 
compared to previous 2 periods (1988–1993, 13.2%; 1994–
2002, 55.2%; and 2003–2011, 81.7%). PET-CT was also used 
more frequently in the third period compared to previous 2 
periods (1988–1993, 2.8%; 1994–2002, 2.9%; and 2003–2011, 
72.9%). However, bone scan, abdominal CT, and abdominal US 
were decreased in the third period compared to previous 2 
periods—bone scan (1988–1993, 71.8%; 1994–2002, 71.1%; and 
2003–2011, 16.6%), abdominal CT and abdominal US (1988–
1993, 80.6%; 1994–2002, 55.7%; and 2003–2011, 14.7%). 
Details of diagnostic imaging studies are shown in Table 2. 
3. Treatment
Of the 1,445 patients, 894 (61.9%) received CCRT and 551 
(38.1%) received RT alone. Neoadjuvant chemotherapy 
was given before RT to 468 patients (32.4%) and adjuvant 
chemotherapy was given after RT to 366 patients (25.3%). 
Grouping the patients by the treatment modalities, CCRT 
alone without neoadjuvant or adjuvant chemotherapy was 
the most common treatment regimen (27.5%). CCRT followed 
by adjuvant chemotherapy (21.3%) and RT alone without 
Table 1. Patients’ characteristics
Characteristics No. (%)
Age (yr), median (range)
Gender
   Male
   Female
ECOG performance status
   0–1
   2
   Unknown
Pathology
   Keratinizing SqCC
   Non-keratinizing carcinoma
   Others
   Unknown
EBV
   Positive
   Negative
   Unknown
T stage
   T1
   T2
   T3
   T4
   Unknown
N stage
   N0
   N1
   N2
   N3
   Unknown
AJCC stage
   I
   II
   III
   IV
 51 (18–86)
 
1,054 (72.9)
 391 (27.1)
 
1,271 (88.0)
 65 (4.5)
109 (7.5)
 
225 (15.6)
1,176 (81.4)
16 (1.1)
28 (1.9)
 
164 (11.3)
 94 (6.5)
1,187 (82.1)
 
404 (28.0)
393 (27.2)
282 (19.5)
365 (25.3)
 1 (0.1)
 
266 (18.4)
380 (26.3)
624 (43.2)
174 (12.0)
 1 (0.1)
 
71 (4.9)
279 (19.3)
577 (39.9)
518 (35.8)
ECOG, Eastern Cooperative Oncology Group; SqCC, squamous 
cell carcinoma; AJCC, American Joint Committee on Cancer; EBV, 
Epstein-Barr virus.
Table 2. Changes in diagnostic modalities over the periods studied
Imaging modality 1988–1993 1994–2002 2003–2011 Total period
Neck CT 
Neck MRI
PET-CT
Bone scan
Abdomen CT or US
39 (97.5)
5 (13.2)
1 (2.8)
28 (71.8)
29 (80.6)
455 (92.1)
265 (55.2)
14 (2.9)
344 (71.1)
267 (55.7)
865 (95.1)
738 (81.7)
658 (72.9)
146 (16.6)
129 (14.7)
1,359 (94.1)
1,008 (69.8)
673 (46.6)
518 (35.8)
425 (29.4)
Values are presented as number (%).
CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; US, ultra-
sonography.
191
Patterns of care for nasopharyngeal carcinoma
www.e-roj.orghttp://dx.doi.org/10.3857/roj.2015.33.3.188
neoadjuvant or adjuvant chemotherapy (18.5%) were the next 
common treatment regimens. The more details are presented 
in Table 3.
Treatment regimens showed a difference between the 
AJCC stages. Patients with stage III and IV disease, received 
CCRT more often than those with stage I and II (stage I, 
14.1%; stage II, 53.4%; stage III, 64.6%; and stage IV, 69.9%). 
Neoadjuvant and adjuvant chemotherapies were also delivered 
more often to patients with more advanced diseases—
neoadjuvant chemotherapy (stage I, 8.5%; stage II, 29.4%; 
stage III, 35.4%; and stage IV, 34.0%), adjuvant chemotherapy 
(stage I, 0%; stage II, 21.1%; stage III, 26.5%; and stage IV, 
29.7%). Treatment regimens also showed a difference over the 
periods. CCRT increased remarkably from 15.0% in 1988–1993 
to 75.1% in 2003–2011. Neoadjuvant chemotherapy steadily 
declined from 55.0% to 28.5% during studied period and 
adjuvant chemotherapy did not show a remarkable change 
after 1994 (Table 4). 
Of the 894 patients who received CCRT, 768 (85.9%) 
completed chemotherapy (Table 5). Weekly scheduled 
chemotherapy was given to 350 patients (39.1%). More 
Table 3. Combination of treatment regimens
No. (%)
Treatment
   RT
      CCRT
      RT alone 
   Neoadjuvant CTx
      Yes
      No
   Adjuvant CTx
      Yes
      No
Combination of treatment modalities
   RT alone
   CCRT alone
   RT + adjuvant CTx
   CCRT + adjuvant CTx
   Neoadjuvant CTx + RT
   Neoadjuvant CTx + CCRT
   Neoadjuvant CTx + RT + adjuvant CTx
   Neoadjuvant CTx + CCRT + adjuvant CTx
 
 
 894 (61.9)
 551 (38.1)
 
 468 (32.4)
 977 (67.6)
 
 366 (25.3)
1,079 (74.7)
 
 267 (18.5)
 398 (27.5)
 4 (0.3)
 308 (21.3)
 251 (17.4)
 163 (11.3)
 29 (2.0)
 25 (1.7)
RT, radiotherapy; CCRT, concurrent chemoradiotherapy; CTx, che-
motherapy.
Table 4. Treatment regimens over the periods studied
Treatment 1988–1993 1994–2002 2003–2011 Total period
RT
   CCRT
   RT alone 
Neoadjuvant chemotherapy
   Yes
   No
Adjuvant chemotherapy
   Yes
   No
 
 6 (15.0)
34 (85.0)
 
22 (55.0)
18 (45.0)
 
3 (7.5)
37 (92.5)
 
205 (41.4)
290 (58.6)
 
187 (37.8)
308 (62.2)
 
113 (22.8)
382 (77.2)
 
683 (75.1)
227 (24.9)
 
259 (28.5)
651 (71.5)
 
250 (27.5)
660 (72.5)
 
894 (61.9)
551 (38.1)
 
468 (32.4)
977 (67.6)
 
 366 (25.3)
1,079 (74.7)
Values are presented as number (%).
RT, radiotherapy; CCRT, concurrent chemoradiotherapy.
Table 5. Concurrent chemotherapy schedule and regimen
Variable No. (%)
Completion 
   Completed
   Not completed
   Unknown
Schedule
   Weekly
      1–4 cycles
      ≥5 cycles
      Unknown
   Every 3 or 4 weeks
      1 cycle
      2–3 cycles
      ≥4 cycles
      Unknown
   Unknown
Chemotherapy regimen
   Cisplatin
   FP
   DP
   FDP
   Miscellaneous
   Unknown
 
768 (85.9)
103 (11.5)
23 (2.6)
 
350 (39.1)
66 (18.9)
264 (75.5)
20 (5.7)
511 (57.2)
24 (4.7)
465 (91.0)
20 (4.0)
 2 (0.4)
33 (3.7)
 
727 (81.3)
72 (8.1)
26 (2.9)
12 (1.3)
44 (4.9)
13 (1.5)
FP, 5-fluorouracil + cisplatin; DP, docetaxel + cisplatin; FDP, 5-fluo-
rouracil + docetaxel + cisplatin.
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than five cycles were given to 75.5% of the 350 patients. 
Approximately 57.2% of the patients received chemotherapy 
every 3 or 4 weeks, and most patients (91.0%) were given 
two or three cycles of chemotherapy. The most commonly 
used chemotherapy regimen in CCRT was cisplatin (81.3%). 
Neoadjuvant chemotherapy and adjuvant chemotherapy were 
completed in 82.7% and 80.3% of patients, respectively. In both 
neoadjuvant and adjuvant chemotherapies, 5-fluorouracil/
cisplatin was the most commonly used regimen (neoadjuvant 
chemotherapy, 49.8%; adjuvant chemotherapy, 87.2%). More 
details about neoadjuvant and adjuvant chemotherapies are 
shown in Table 6.
As for RT, 98.1% of the patients completed the whole 
course of treatment. Patients received RT using 4 techniques: 
the two-dimensional RT (2DRT) technique (24.6%), 2DRT 
and 3DRT combined technique (11.7%), 3DRT technique 
(28.0%), and intensity-modulated RT (IMRT) technique 
(35.7%). Changes in the four RT techniques over time were 
observed. The 2DRT technique was performed on 92.5% of 
the patients in 1988–1993. In 2003–2011, the 3DRT and 
IMRT techniques were on 35.5% and 56.5% of the patients, 
respectively (Fig. 1). Radiation target volume was grouped as 
primary nasopharyngeal tumor, grossly enlarged nodes, high 
risk lymphatic chain and low risk lymphatic chain. High risk 
lymphatic chain was defined as the involved cervical nodal 
area. Low risk lymphatic chain was defined as the clinically 
and radiologically uninvolved cervical nodal areas, deemed 
as elective nodal regions. Different RT dose was given to 
each target volume, respectively. For the primary tumor and 
gross nodes, a radiation dose of 66–72 Gy was given to the 
most patients (Table 7). The median dose for primary tumors 
was 70.0 Gy, and that for gross nodes was 67.5 Gy. The 
conventional daily dose (1.8–2.0 Gy) was used to two-thirds 
of the patients. A fractional dose of over 2.0 Gy was given to 
approximately 30% of the patients. The median dose given to 
high-risk lymphatic chain was 58.1 Gy, and that to low-risk 
lymphatic chain was 48.0 Gy. A daily dose to lymphatic chains 
was rarely elevated over 2.0 Gy. When RT doses were compared 
according to RT techniques, the percentage of patients who 
received 66–72 Gy to primary tumor was not quite different 
Table 6. Schedule and regimen of neoadjuvant chemotherapy and 
adjuvant chemotherapy
No. (%)
Neoadjuvant chemotherapy
   Completion
      Completed
      Not completed
      Unknown
   Regimen
      FP
      FDP
      DP
      Miscellaneous
      Unknown
   Cycle
      1
      2
      3
      ≥4
      Unknown
Adjuvant chemotherapy
   Completion
      Yes
      No
      Unknown
   Regimen
      FP
      FDP
      DP
      Miscellaneous
      Unknown
   Cycle
      1–2
      3
      4
      ≥5
      Unknown
 
 
387 (82.7)
21 (4.5)
 60 (12.8)
 
233 (49.8)
101 (21.6)
 65 (13.9)
 54 (11.5)
15 (3.2)
 
39 (8.3)
 82 (17.5)
308 (65.8)
24 (5.1)
15 (3.2)
 
 
294 (80.3)
 60 (16.4)
12 (3.3)
 
319 (87.2)
18 (4.9)
 9 (2.5)
18 (4.9)
 2 (0.5)
 
 90 (24.6)
199 (54.4)
 55 (15.0)
21 (5.8)
 1 (0.3)
FP, 5-fluorouracil + cisplatin; DP, docetaxel + cisplatin; FDP, 5-fluo-
rouracil + docetaxel + cisplatin.
Fig. 1. Trend in radiotherapy technique over the periods studied. 
IMRT, intensity-modulated radiotherapy; 3DRT, three-dimensional 
radiotherapy; 2DRT, two-dimensional radiotherapy.
1988-1993 1994-2002 2003-2011 Total period
IMRT
2DRT & 3DRT
3DRT
2DRT
0 (0.0%)
1 (2.5%)
2 (5.0%)
37
(92.5%)
2 (0.4%)
80
(16.2%)
129
(26.1%)
283
(57.3%)
514
(56.5%)
323
(35.5%)
38 (4.2%)
35 (3.8%)
516
(35.7%)
404
(28.0%)
169
(11.7%)
355
(24.6%)
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between RT techniques (2DRT, 70.7%; 3DRT, 88.6%; and IMRT, 
60.3%). However, as for dose given to high risk lymphatic 
chain, 67.4% of patients treated with 2DRT received below 55 
Gy while 64.8% of patients treated with IMRT received 55–60 
Gy. Patients given doses below 55 Gy to low risk lymphatic 
chain were 70.6% with 2DRT and 58.0% with IMRT. Boost RT 
was given to 40 patients (2.8%) using IMRT (1.0%), stereotactic 
body radiotherapy (1.0%), and brachytherapy (0.8%). 
4. Response and treatment outcome
Responses were evaluated by physical examination (62.1%), 
neck CT (56.5%), neck MRI (32.2%), PET-CT (14.1%), and 
histopathological examination (5.0%). The number of patients 
who showed clinical responses was 1,353 (93.6%), and the 
more details were as follows: complete response, 1,025 (70.9%); 
partial response, 328 (22.7%); stable disease, 35 (2.4%); and 
progressive disease, 15 (1.0%). The 5-year OS rates were 73.6% 
for the whole group and those for individual stages were as 
follows: stage I, 96.3%; stage II, 86.2%; stage III, 77.4%; and 
stage IV, 60.4%. The 5-year OS rate showed a significantly 
better outcome in the third period compared to previous 2 
periods (1988–1993, 63.5%; 1994–2002, 64.8%; 2003–2011, 
79.9%; p < 0.001) (Fig. 2).
In total, 452 patients (31.2%) had recurrences: 235 patients 
(16.2%) showed locoregional recurrences without distant 
metastasis, 197 patients (13.6%) showed distant metastases 
only, and 20 patients (1.4%) showed both. Recurrent patients 
received salvage treatment including surgery (15.3%), re-
irradiation (40.1%), and chemotherapy (50.0%). RT techniques 
used in re-irradiation was 3DRT (46.4%), fractionated 
Table 7. Radiotherapy dose schedule
Dose prescription Value
Primary tumor dose 
   Total dose (Gy)
      ≤60 
      >60 and ≤66 
      >66 and ≤72
      >72
      Unknown
   Daily dose (Gy)
      ≥1.8 and ≤2.0
      >2.0 and ≤2.2
      >2.2 and ≤2.4
      >2.4
      Unknown
Gross node dose 
   Total dose (Gy)
      ≤60 
      >60 and ≤66 
      >66 and ≤72
      >72
      Unknown
   Daily dose (Gy)
      ≥1.8 and ≤2.0
      >2.0 and ≤2.2
      >2.2 and ≤2.4
      >2.4
      Unknown
High risk lymphatic chain 
   Total dose (Gy)
      ≤50 
      >50 and ≤55
      >55 and ≤60
      >60
      Unknown
   Daily dose (Gy)
      <1.8 
      ≥1.8 and ≤2.0
      >2.0
      Unknown
Low risk lymphatic chain 
   Total dose (Gy)
      ≤45 
      >45 and ≤50 
      >50 and ≤55
      >55
      Unknown
   Daily dose (Gy)
      <1.6
      ≥1.6 and <1.8
      ≥1.8 and ≤2.0 
      Unknown
70.0 (45.0–100.2)
36 (2.5)
245 (17.0)
1,030 (71.3)
134 (9.3)
0 (0)
2.0 (1.8–3.0)
972 (67.3)
174 (12.0)
264 (18.3)
3 (0.2)
32 (2.2)
67.5 (30.6–80.0)
237 (16.4)
267 (18.5)
554 (38.3)
44 (3.0)
353 (23.7)
2.0 (1.8–3.0)
724 (50.1)
127 (8.8)
247 (17.1)
2 (0.1)
345 (23.9)
58.1 (30.6–75.6)
97 (6.7)
306 (21.2)
423 (29.3)
88 (6.1)
531 (36.7)
1.8 (1.5–2.5)
34 (2.4)
782 (54.1)
98 (6.8)
531 (36.7)
48.0 (5.0–71.2)
434 (30.0)
192 (13.3)
289 (20.0)
89 (6.2)
441 (30.5)
1.8 (1.4–2.0)
4 (0.3)
186 (12.9)
814 (56.3)
441 (30.5)
Values are presented as median (range) or number (%).
0
0.8
0.6
0.4
0.2
O
v
e
ra
ll
s
u
rv
iv
a
l
Follow-up time (mo)
0
96
1.0
12 24 36 48 60 72 84
1988 1993 period-
1994-2002 period
2003-2011 period
Fig. 2. Overall survival according to period. The 5-year overall 
survival rates were 63.5% for 1988–1993, 64.8% for 1994–2003, 
and 79.9% for 2004–2011 (p < 0.001).
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stereotactic radiotherapy (23.2%), or IMRT (21.4%). Patients 
received other treatments as follows: 3 patients received 
CyberKnife-based radiosurgery, 1 patient brachytherapy, 1 
patient gamma knife-based radiosurgery, and 1 patient proton 
therapy.
Discussion and Conclusion
To the best of our knowledge, this is the first report on 
the patterns of care for patients with NPC in South Korea. 
This report is based on the data for a large-scaled multi-
institutional study that were collected from 1,445 patients. 
We assessed the patterns of care over time and demonstrated 
that management for NPC patients in South Korea have 
been improved in accordance with international guidelines. 
According to the current guidelines, neck CT, neck MRI, and 
PET-CT are recommended for stage evaluation at diagnosis. 
Although CT provides fundamental anatomic information 
for defining RT target volume, CT has limitations in exact 
delineation of tumors that extend to adjacent structures. 
MRI is superior to CT to detect intracranial involvement, skull 
bone invasion, or parapharyngeal infiltration. Ng et al. [6] 
documented that T-staging was changed in 26.9% of patients 
after comparing CT with MRI and N-staging was upstaged in 
6%. Lee et al. [7] also reported that patients staged by MRI 
before RT achieved significantly higher local tumor control 
rate and survival rate than the patients staged by CT (MRI 
staged T3-4 vs. CT staged T3-4: the 5-year local failure-free 
rate, 83% vs. 76%; the 5-year OS, 72% vs. 63%). To better 
define the anatomical extent, both CT and MRI findings should 
be incorporated into target contouring. Also, PET-CT has been 
reported to add value on CT and MRI findings, providing 
metabolic imaging. PET-CT is able to detect metastatic lymph 
nodes that may appear normal on CT and/or MRI. Kresnik et al. 
[8] showed that PET led to an upstaging in 20.8% of patients 
by detecting lymph node metastases which was negative 
on CT and MRI. Further, PET-CT provides better sensitivity 
and specificity of detecting distant metastasis compared to 
conventional images such as bone scan, abdominal CT or 
abdominal US [9,10]. In our study, MRI and PET-CT had been 
more frequently used in 2003–2011 compared to previous 2 
periods. About three-fourths of patients were evaluated by 
neck CT, neck MRI and PET-CT in 2003–2011. Performance 
of the three imaging modality has become the mainstay of 
diagnostic evaluation.
Changes in treatment regimens over time were also 
observed. As NPC is not only radiosensitive but chemosensitive 
tumor, many trials investigated advantage of concurrent 
chemotherapy for NPC to improve locoregional control. Al-
Sarraf et al. [11] have reported that cisplatin-based CCRT 
improved the 3-year survival rate from 47% to 78% compared 
to RT alone. After this intergroup study 0099, randomized 
trials with similar setting confirmed the benefit of CCRT that 
resulted in better survival outcome than RT alone [12-14]. 
Update of meta-analysis of chemotherapy in nasopharynx 
carcinoma (MAC-NPC) reported the results of analysis from 
19 trials and 4,806 patients that the addition of concomitant 
chemotherapy to RT significantly improved OS [15]. Though 
it was not directly compared in trials or meta-analyses, either 
weekly cisplatin (30–40 mg/m2) or 3-weekly high-dose cisplatin 
(100 mg/m2) was thought to be similarly effective. Because 
only 63% of patients completed all course of concurrent 
chemotherapy in intergroup study 0099, effort to set the 
optimal dose of chemotherapy was done in following studies. 
Lee et al. [16] reported that dose of cisplatin during CCRT had 
significant impact on locoregional failure-free rate and OS. The 
locoregional failure-free rate for patients who received 2–3 
concurrent cycles of 3-weekly high-dose cisplatin (100 mg/m2) 
was significantly higher than those with 0–1 cycles. Loong et 
al. [17] showed that patients who received more than 5 cycles 
of weekly cisplatin (40 mg/m2) had significantly better OS than 
those who did not. It is generally accepted that a cumulative 
dose of 200 mg/m2 cisplatin during CCRT is sufficient. In the 
present study, CCRT was performed on 15.0% of patients 
who had stage II–IV disease in 1988–1993; however, it 
was performed on 78.8% of patients at the same stages in 
2003–2011. For total studied period, the most commonly used 
chemotherapy regimen for CCRT was cisplatin (81.3%). Of the 
894 patients who treated with CCRT, 749 patients (83.8%) 
received more than 5 cycles of weekly chemotherapy or more 
than 2 cycles of 3-weekly high-dose chemotherapy.
As most NPC patients present with advanced disease 
at diagnosis and distant metastasis is the main pattern of 
failure, efficacy of systemic chemotherapy have been studied 
extensively. Neoadjuvant chemotherapy was tried to reduce 
tumor burden before RT and to eradicate micro-metastases. 
Several phase II trials showed high overall response rate of 
cisplatin-based combination chemotherapy ranging from 75% 
to 90% [18-20]. However, prospective randomized trials failed 
to demonstrate improvement in survival [21-23]. Adjuvant 
chemotherapy was included in several trials investigating 
efficacy of CCRT, because it was performed in intergroup 
study 0099. Though CCRT followed by adjuvant chemotherapy 
showed significantly better treatment outcome than RT 
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alone, randomized trials evaluating the role of adjuvant 
chemotherapy demonstrated no survival benefit [24,25]. 
Meta-analysis reported in 2015 by Yan et al. [26], showed no 
difference for survival outcome between CCRT alone, CCRT 
after neoadjuvant chemotherapy, and CCRT followed by 
adjuvant chemotherapy. According to guidelines, CCRT with 
or without adjuvant chemotherapy is the standard treatment, 
but neoadjuvant chemotherapy is not recommended [5]. 
Decision for adjuvant chemotherapy is left for each clinician. 
Percentages of patients who received neoadjuvant and 
adjuvant chemotherapy in this study were not much high 
as 32.4% and 25.3%, respectively. Both showed a tendency 
to increase in patients with more advanced stage. Over the 
period, neoadjuvant chemotherapy declined by almost half, 
reflecting the negative results of trials. Adjuvant chemotherapy 
has maintained a similar level after 1994. The most commonly 
used regimen of adjuvant chemotherapy was 5-fluorouracil/
cisplatin (87.2%) which was used in intergroup study 0099. 
The regimens of neoadjuvant chemotherapy were more 
variable but 5-fluorouracil/cisplatin was the most common 
(49.8%). More studies investigating the role of neoadjuvant or 
adjuvant chemotherapy is needed to propose a clear guideline.
Advances in RT techniques were remarkable over the 
periods studied. In 1988–1993, 92.5% of the patients were 
treated with the 2DRT technique; in 2003–2011, the 3DRT 
technique and IMRT were performed on 92.0% of patients. 
During the whole period of 25 years, the mainstream of RT 
for NPC patients was changed from the 2DRT through 3DRT, 
in currently IMRT. RT dose schedules also changed according 
to advances in RT techniques. Total RT doses given to primary 
tumor were not quite different between patients treated 
with 2DRT technique and those treated with IMRT. However, 
daily doses delivered with 2DRT were 1.8–2.0 Gy in 97.7% of 
patients, while with IMRT over 2.0 Gy in 81.5%. Also, increase 
of RT doses given to high risk lymphatic chain was observed; 
67.4% of patients received doses below 55 Gy with 2DRT 
technique but 64.8% of patients over 55 Gy with IMRT.
In the 2DRT era, doses of 66–70 Gy was delivered to primary 
tumor via laterally opposed fields. It could deliver tumoricidal 
doses to the primary tumor, but compromise of target 
coverage was inevitable because of proximity to critical organs 
such as brainstem or temporal lobe. Delivery of sufficient 
dose to lymphatic area was also hardly achievable. The 5-year 
local control was reported as 78%–85% and the 5-year OS 
was 50%–75% in 2DRT era [7,27-30]. In comparison to 2DRT, 
IMRT can make highly conformal isodose lines and prevent 
target volume from being underdosed. This improved dose 
distributions potentially lead to improved tumor control and 
better survival outcomes [31,32]. The results of IMRT treated 
by Lee et al. [33] showed 97% local progression-free survival 
and 88% OS with 4-year follow-up. Owing to the favorable 
outcomes, IMRT became the major RT technique to treat NPC 
patients nowadays. The present study revealed that IMRT 
enables radiation oncologists to elevate daily dose to the gross 
tumor over 2 Gy, and also elevate total dose given to the high 
risk lymphatic chain.
This study has the limitation in terms of data quality 
because missing data were included in the dataset. This was 
unavoidable because patient data were collected retrospectively 
through surveys of multiple institutions. However, this study 
has a large sample size, which sufficiently showed the patterns 
of care for NPC patients in South Korea. Also, data on RT 
planning and dosimetry were not collected so the comparison 
of the RT plans according to RT techniques could not be done.
In conclusion, there have been advances in the management 
of NPC patients in South Korea. Diagnostic imaging studies 
including CT, MRI and PET-CT have been more frequently 
used and CCRT have been performed in more patients. Also, 
RT techniques and dose prescription have been advanced 
remarkably to adopt the IMRT technique and dose escalation. 
Treatment for NPC patients in South Korea reflected the up-
to-date results of trials and advanced in accordance with the 
international guidelines.
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